TherapeuticsMD (TXMD) Long-Term Deferred Tax (2022 - 2024)

TherapeuticsMD (TXMD) has reported Long-Term Deferred Tax for 3 consecutive years, with $167.4 million the latest figure, recorded in Q4 2024.

• For the quarter ending Q4 2024, Long-Term Deferred Tax rose 5.9% year-over-year to $167.4 million; the trailing twelve-month figure through Dec 2024 stood at $167.4 million (up 5.9% YoY), and the FY2024 full-year result was $167.4 million, up 5.9% from the prior year.
• Long-Term Deferred Tax advanced to $167.4 million in Q4 2024 per TXMD's latest filing, from $158.0 million in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $176.6 million in Q4 2022 and bottomed at $158.0 million in Q4 2023.
• Historically, Long-Term Deferred Tax has averaged $167.3 million across 3 years, with a median of $167.4 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Long-Term Deferred Tax retreated 10.53% in 2023, then climbed 5.9% in 2024.
• Over 3 years, Long-Term Deferred Tax stood at $176.6 million in 2022, then declined by 10.53% to $158.0 million in 2023, then increased by 5.9% to $167.4 million in 2024.
• According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $167.4 million, $158.0 million, and $176.6 million for Q4 2024, Q4 2023, and Q4 2022 respectively.